These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26999770)

  • 1. Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
    Huerta-García G; Vazquez-Rosales JG; Mata-Marín JA; Peregrino-Bejarano L; Flores-Ruiz E; Solórzano-Santos F
    Pediatr Res; 2016 Jul; 80(1):54-9. PubMed ID: 26999770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
    Corrigan B; Mukui I; Mulenga L; Mthethwa N; Letsie M; Bruno S; Rakhmanina N
    Pediatr Infect Dis J; 2018 Jul; 37(7):669-672. PubMed ID: 29140932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.
    Briz V; Palladino C; Navarro M; Jiménez de Ory S; González-Tomé M; León J; Núñez-Cuadros E; de José M; Ramos J; Muñoz-Fernández M
    HIV Med; 2011 Aug; 12(7):442-6. PubMed ID: 21395964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
    Viganò A; Meroni L; Marchetti G; Vanzulli A; Giacomet V; Fasan S; Pradella A; Cerini C; Zuccotti GV
    Antivir Ther; 2008; 13(6):839-43. PubMed ID: 18839785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana.
    Kirk BL; Gomila A; Matshaba M; Marape M; Joel DR; Anabwani G; Tolle MA
    J Int Assoc Provid AIDS Care; 2013; 12(2):90-4. PubMed ID: 23315674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
    Domínguez-Hermosillo JC; Mata-Marin JA; Herrera-González NE; Chávez-García M; Huerta-García G; Nuñez-Rodríguez N; García-Gámez JG; Jiménez-Romero A; Gaytán-Martínez JE
    J Infect Dev Ctries; 2016 Sep; 10(9):982-987. PubMed ID: 27694731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.
    Masquelier B; Capdepont S; Neau D; Peuchant O; Taupin JL; Coakley E; Lie Y; Carpentier W; Dabis F; Fleury HJ;
    AIDS; 2007 Jan; 21(1):103-6. PubMed ID: 17148975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
    Thuret I; Chaix ML; Tamalet C; Reliquet V; Firtion G; Tricoire J; Rabaud C; Frange P; Aumaître H; Blanche S
    AIDS; 2009 Nov; 23(17):2364-6. PubMed ID: 19823069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.